News | November 12, 2025
JB Pharma Q2 PAT up 19 % at Rs. 208 Cr
Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore
Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore
Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo
OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
Venus Remedies now has 29 active product approvals in Vietnam alone
The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline
Sumatriptan injection is indicated in adults for the acute treatment of migraine
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets
Senores Pharmaceuticals (SPI) acquired 51% stake in Zoraya Pharmaceuticals
Speakers are: Dr. Alok Khullar, Senior Technology Leader, Pidilite Industries; Dr. Kamlesh Pai Fondekar, Head - R&D, Godrej Agrovet; Dr. Hiten Mehta, Head - R&D (Chlor-Alkali), Aditya Birla Chemicals; Dr. Anil Kumar Soni, Head - Application Development, R&D, Clariant Chemicals India; Dr. Rupak Paul, Deputy General Manager – Formulation, Rallis India; Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals; and Pravin Prashant, Executive Editor, Indian Pharma Post
Subscribe To Our Newsletter & Stay Updated
